Correlation Between Beam Therapeutics and Crispr Therapeutics

Can any of the company-specific risk be diversified away by investing in both Beam Therapeutics and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Beam Therapeutics and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Beam Therapeutics and Crispr Therapeutics AG, you can compare the effects of market volatilities on Beam Therapeutics and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Beam Therapeutics with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Beam Therapeutics and Crispr Therapeutics.

Diversification Opportunities for Beam Therapeutics and Crispr Therapeutics

0.58

Correlation Coefficient

Beam Therapeutics  Crispr Therapeutics

Very weak diversification

The 3 months correlation between Beam and Crispr is 0.58. Overlapping area represents the amount of risk that can be diversified away by holding Beam Therapeutics and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and Beam Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Beam Therapeutics are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of Beam Therapeutics i.e., Beam Therapeutics and Crispr Therapeutics go up and down completely randomly.

Pair Corralation between Beam Therapeutics and Crispr Therapeutics

Given the investment horizon of 90 days Beam Therapeutics is expected to generate 1.17 times less return on investment than Crispr Therapeutics. In addition to that, Beam Therapeutics is 1.48 times more volatile than Crispr Therapeutics AG. It trades about 0.03 of its total potential returns per unit of risk. Crispr Therapeutics AG is currently generating about 0.05 per unit of volatility. If you would invest  4,772  in Crispr Therapeutics AG on August 30, 2024 and sell it today you would earn a total of  312.00  from holding Crispr Therapeutics AG or generate 6.54% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Beam Therapeutics  vs.  Crispr Therapeutics AG

Beam Therapeutics

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Beam Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, Beam Therapeutics may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Crispr Therapeutics

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Crispr Therapeutics AG are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, Crispr Therapeutics may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Pair Trading with Beam Therapeutics and Crispr Therapeutics

The main advantage of trading using opposite Beam Therapeutics and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Beam Therapeutics position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.

The idea behind Beam Therapeutics and Crispr Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.